A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
A Randomized, Multicenter, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy in Male Androgenetic Alopecia Treated With HMI-115 Over a 24-Week Treatment Period
In the register
The register attaches this trial to HMI-115 (Hope Medicine), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd
- Participants (registry)
- 192
- Start
- September 2023
- Primary completion
- August 2024
- Study completion
- November 2024
- Last registry update
- June 2025
- Countries
- China
Conditions studied: Androgenetic Alopecia
Interventions: placebo-Q2W, HMI-115-120mg-Q4W, HMI-115-240mg-Q4W, HMI-115, 240mg-Q2W
Other trials of HMI-115
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.